Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.41 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.41 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.40 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL403906 | 0.83 | RAB9A (0.45) | ADAMTS4MMP13MAOB | |
| SCHEMBL7540932 | 0.80 | SLC1A1 (0.51) | MAOB | |
| SCHEMBL7540938 | 0.80 | SLC1A1 (0.51) | MAOB | |
| SCHEMBL23321020 | 0.80 | HCAR2 (0.48) | FFAR1FFAR4ADAMTS4MMP13MAOB | |
| SCHEMBL408720 | 0.76 | SLC7A5 (0.42) | FOLH1MRGPRX4 | |
| SCHEMBL408721 | 0.76 | SLC7A5 (0.42) | FOLH1MRGPRX4 | |
| SCHEMBL800275 | 0.75 | GLA (0.54) | FFAR1FFAR4ADAMTS4MMP13MAOB | |
| SCHEMBL13544211 | 0.75 | FFAR1 (0.50) | FFAR1FFAR4FOLH1MAOBGLA | |
| SCHEMBL5089141 | 0.75 | FFAR1 (0.48) | FFAR1FFAR4FOLH1ADAMTS4MMP13 | |
| SCHEMBL7543579 | 0.74 | SLC1A3 (0.59) | ADAMTS4MMP13MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414341-A2 | OXADIAZOLE DERIVATIVES | Merck Serono SA (CH) | 2012-02-08 | — | — | EP | disclosed |
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | MERCK SERONO SA (CH) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022109-A1 | OXADIAZOLE DERIVATIVES | OXA1L, HLA-DRB1, SSB | FFAR1 2388/4885FFAR4 2598/4885FOLH1 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.